Children’s Oncology Group

@COGorg

The Children’s Oncology Group (COG) is the world’s largest organization devoted exclusively to childhood and adolescent cancer research.

Vrijeme pridruživanja: svibanj 2018.

Tweetovi

Blokirali ste korisnika/cu @COGorg

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @COGorg

  1. Prikvačeni tweet

    Vincristine Shortage – A Letter to the Childhood Cancer Community from Dr. Peter Adamson, Chair of the Children's Oncology Group

    Prikaži ovu nit
    Poništi
  2. 30. sij

    Mixed‐phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force

    Poništi
  3. proslijedio/la je Tweet

    Newly Activated Trial: (ACNS1833) A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma, led by . Learn more:

    Poništi
  4. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children’s Oncology Group ARAR0331 Study

    Poništi
  5. Poništi
  6. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant.

    Prikaži ovu nit
    Poništi
  7. New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

    Prikaži ovu nit
    Poništi
  8. Prikaži ovu nit
    Poništi
  9. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study

    Poništi
  10. Results of Children’s Oncology Group Trial AALL0331 suggest intensified postinduction therapy does not significantly improve outcomes over standard consolidation for patients with standard-risk ALL

    Prikaži ovu nit
    Poništi
  11. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet

    NCI Press Release: trial AALL1331 found that after completion of reinduction therapy, blinatumomab is superior to standard chemotherapy for certain children and young adults with relapsed B-cell acute lymphoblastic leukemia. Learn more:

    Poništi
  13. proslijedio/la je Tweet
    25. stu 2019.

    'Tis the season! The MLS WORKS Holiday Auction is now open! Bid on match-used & autographed jerseys & match balls with net proceed benefitting . ➡️:

    Poništi
  14. proslijedio/la je Tweet
    12. stu 2019.

    Want to improve care and outcomes for cancer patients? Join the webinar on dec 3rd to learn how to increase enrollment onto clinical trials. Need AYAs on trials to determine optimal treatment approaches.

    Poništi
  15. proslijedio/la je Tweet
    30. lis 2019.

    ALL-directed chemo w/o hematopoietic stem cell transplantation may be sufficient therapy for most children with WHO2016-defined MPAL. The proposed prospective trial will investigate this approach and explore MPAL genomics and correlative biology.

    Poništi
  16. If you missed the Vincristine drug shortage update webinar, it was recorded and available to watch via this link

    Poništi
  17. You are invited to an informational webinar presented by Dr. Peter Adamson, Chair of the Children’s Oncology Group. Dr. Adamson will share information and a perspective on childhood cancer drug shortages, including the current situation with vincristine.

    Poništi
  18. proslijedio/la je Tweet

    You are invited to an informational webinar presented by Dr. Peter Adamson, Chair of the Children’s Oncology Group. Dr. Adamson will share information and a perspective on childhood cancer drug shortages, including the current situation with vincristine.

    Poništi
  19. Dr. Peter Adamson, Chair of the Children’s Oncology Group, was interviewed by about the shortage. . Shortage of critical children’s cancer drug causes concerns nationwide

    Poništi
  20. ....children’s cancer, acute lymphoblastic leukemia, then less often as a maintenance therapy for two to three years. Children newly diagnosed with the leukemia are given the highest priority if vincristine is scarce."

    Prikaži ovu nit
    Poništi
  21. Dr. Peter Adamson quoted in the article, regarding vincristine shortage, "Vincristine is used to treat 80% of the 19,000 children and adolescents diagnosed with cancer each year. It is given once a week for four weeks to induce remission in the most common...

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·